Dr.Reddy’s launches generic version of Ciprodex

The newly launched product will be used to treat ear infections

August 11, 2020 11:30 am | Updated 06:52 pm IST - HYDERABAD:

HYDERABAD, 08/01/2008: Dr. Reddy's Labs: A view of Dr. Reddy's Lab facility near Hyderabad.
Photo: P.V. Sivakumar 08-01-2008

HYDERABAD, 08/01/2008: Dr. Reddy's Labs: A view of Dr. Reddy's Lab facility near Hyderabad. Photo: P.V. Sivakumar 08-01-2008

Pharma major Dr. Reddy’s Laboratories on Tuesday said it has launcheda generic version of Ciprodex (Ciprofloxacin 0.3% and Dexamethasone 0.1%) Otic Suspension, USP, in the U.S. market.

A therapeutic equivalent generic version of Ciprodex (ciprofloxacin 0.3% and dexamethasone 0.1%) Otic Suspension, the product is indicated for treatment of ear infections. Ciprodex is a trademark of Bayer AG.

The launch follows the U.S. Food and Drug Administration (USFDA) approval for its product, Dr. Reddy’s said. Ciprodex brand had U.S. sales of approximately $453 million MAT for the most recent twelve months ended June 2020, the company said citing IQVIA Health numbers.

“We are pleased to launch this first-to-market generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients,” said Marc Kikuchi, CEO, North America Generics, Dr. Reddy’s Laboratories.

“This product demonstrates that we are actively expanding the depth of our portfolio with our first otic suspension dosage form,” he said. Dr. Reddy’s Ciprofloxacin 0.3% and Dexamethasone 0.1% Otic Suspension, USP, is available as 7.5 mL fill in a 10 mL bottle, a release said.

0 / 0
Sign in to unlock member-only benefits!
  • Access 10 free stories every month
  • Save stories to read later
  • Access to comment on every story
  • Sign-up/manage your newsletter subscriptions with a single click
  • Get notified by email for early access to discounts & offers on our products
Sign in

Comments

Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.

We have migrated to a new commenting platform. If you are already a registered user of The Hindu and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.